ARCUTIS BIOTHERAPEUTICS INC

ARQTNASDAQ

🏆 #1608 by market capEarnings Oct 29US Equity

$996.38▼ $7.07 (−0.71%)

Simulated price

🔔

Track ARQT

Get earnings, price moves & breaking news on Telegram

Track

24h▼ 0.7%

7d—

14d—

30d—

ytd—

1y—

🏦Market Cap

$3.36B

Small Cap

📈Revenue Growth (YoY)

+76.1%

High Growth

📊Gross Margin

91.1%

High

💵FCF Margin

—

⚖️P/S Ratio

7.3x

Fair

Otter Score

Fair

No chart data available for ARQT.

Trading Snapshot

Day Range: $981.46 – $1,008.36
52-Week Range: $16.71 – $31.77
Volume: $4.78B
Avg Volume: $4.50B
Shares Outstanding: 125.1M
Next Earnings: Oct 23, 2026

Fundamentals Snapshot

Annual Revenue: $376M
Last Q Revenue: $130M
P/E Ratio: 118.3
P/S Ratio: 7.3x
EPS (TTM): $0.21
Dividend Yield: —
Dilution (1yr): +12.1%

Why Investors Own ARQT

✓High-growth profile — revenue up +3.6% YoY with expanding US Equity exposure.
✓Healthy economics — 62% gross margin and 10% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ARCUTIS BIOTHERAPEUTICS INC

ARQT

Financial Trends

Revenue

$376M▲ +91.3% YoY

Gross Margin

90.2%▲ +0.0% YoY

Operating Income

−$12M▼ −90.5% YoY

Free Cash Flow

−$6M▼ −94.4% YoY

Shares Outstanding

135.6M▲ +12.1% YoY

Net Cash

$37M▲ +$76M YoY

StockOtter · stockotter.space

About ARCUTIS BIOTHERAPEUTICS INC

Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.

🦦